Dr Helen Robinson
Helen has >20 years of experience in oncology research and development, the majority within the DNA Damage Response (DDR) field. She has served as Vice President of Biology at Artios Pharma Ltd since 2017. Since joining Artios, she has overseen the building of the DDR biology platform and continues to lead the biology department, supporting the drug discovery process from target ID through to clinical trials. Prior to Artios, Helen was at MISSION Therapeutics where she was both a team and project leader responsible for various drug discovery efforts up to the preclinical stage, leading both biomarker discovery and new targets functional teams. Before this, Helen was a Research Associate at the University of Cambridge and a Senior Scientist at KuDOS Pharmaceuticals.
Helen holds a PhD in Cancer Sciences from the University of Glasgow and a BSc in Biochemistry with Molecular Biology from the University of Leeds.
Select publications
- Mechanistic insights into the monotherapy and combination potential of FEN1 inhibition in cancer therapy. In Press, Nucleic Acids Res. 2025
- Quantitative, titratable and high-throughput reporter assays to measure DNA double strand break repair activity in cells. Rajendra E et. al. Nucleic Acids Res. 2024 Feb 28;52(4):1736-1752
- Discovery of ART0380, a Potent and Selective ATR Kinase Inhibitor Undergoing Phase 2 Clinical Studies for the Treatment of Advanced or Metastatic Solid Cancers. Carroll CL et. al. J Med Chem. 2024 Dec 26;67(24):21890-21904
- Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types. Pilié PG et. al. Clin Cancer Res. 2024 May 15;30(10):2121-2139
- Small-Molecule Polθ Inhibitors Provide Safe and Effective Tumor Radiosensitization in Preclinical Models. Rodriguez-Berriguete G et. al. Clin Cancer Res. 2023 Apr 14;29(8):1631-1642
- POLQ seals post-replicative ssDNA gaps to maintain genome stability in BRCA-deficient cancer cells. Belan O et. al. Mol Cell. 2022 Dec 15;82(24):4664-4680
- Discovery, Characterization, and Structure-Based Optimization of Small-Molecule In Vitro and In Vivo Probes for Human DNA Polymerase Theta. Stockley ML et. al. J Med Chem. 2022 Oct 27;65(20):13879-13891
- Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Zatreanu D et. al. Nat Commun. 2021 Jun 17;12(1):3636
